These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 9775178

  • 1. [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
    Peyrade F, Taillan B, Lebrun C, Baron V, Dujardin P.
    Rev Med Interne; 1998 May; 19(5):366-72. PubMed ID: 9775178
    [Abstract] [Full Text] [Related]

  • 2. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P.
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [Abstract] [Full Text] [Related]

  • 3. Protein tyrosine kinases and cancer.
    Kolibaba KS, Druker BJ.
    Biochim Biophys Acta; 1997 Dec 09; 1333(3):F217-48. PubMed ID: 9426205
    [No Abstract] [Full Text] [Related]

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 09; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.
    Clin Cancer Res; 1998 Jul 09; 4(7):1661-72. PubMed ID: 9676840
    [Abstract] [Full Text] [Related]

  • 6. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H, Affleck K, Stubberfield C, Dean C.
    Int J Oncol; 1998 Aug 09; 13(2):335-42. PubMed ID: 9664130
    [Abstract] [Full Text] [Related]

  • 7. Rational therapeutic intervention in cancer: kinases as drug targets.
    Sawyers CL.
    Curr Opin Genet Dev; 2002 Feb 09; 12(1):111-5. PubMed ID: 11790564
    [Abstract] [Full Text] [Related]

  • 8. ErbB-targeted therapeutic approaches in human cancer.
    Arteaga CL.
    Exp Cell Res; 2003 Mar 10; 284(1):122-30. PubMed ID: 12648471
    [Abstract] [Full Text] [Related]

  • 9. Activation of tyrosine kinases in cancer.
    Vlahovic G, Crawford J.
    Oncologist; 2003 Mar 10; 8(6):531-8. PubMed ID: 14657531
    [Abstract] [Full Text] [Related]

  • 10. [Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
    Hochhaus A, Lahaye T, Kreil S, Berger U, Metzgeroth G, Hehlmann R.
    Onkologie; 2001 Sep 10; 24 Suppl 5():65-71. PubMed ID: 11600816
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor pathway inhibitors.
    Baselga J, Cortes J.
    Cancer Chemother Biol Response Modif; 2005 Sep 10; 22():205-23. PubMed ID: 16110613
    [No Abstract] [Full Text] [Related]

  • 12. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E.
    Med Klin (Munich); 2002 Jan 15; 97 Suppl 1():2-6. PubMed ID: 11831067
    [Abstract] [Full Text] [Related]

  • 13. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N.
    Rinsho Byori; 2004 Feb 15; 52(2):136-44. PubMed ID: 15027317
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.
    J Neurooncol; 2006 Jan 15; 76(2):105-9. PubMed ID: 16205964
    [Abstract] [Full Text] [Related]

  • 15. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB.
    Proc Natl Acad Sci U S A; 1995 Mar 28; 92(7):2558-62. PubMed ID: 7708684
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain.
    Penar PL, Khoshyomn S, Bhushan A, Tritton TR.
    Neurosurgery; 1997 Jan 28; 40(1):141-51. PubMed ID: 8971836
    [Abstract] [Full Text] [Related]

  • 17. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
    Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK, Bhatia R.
    Cancer Res; 2004 Aug 01; 64(15):5322-31. PubMed ID: 15289338
    [Abstract] [Full Text] [Related]

  • 18. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D.
    Semin Oncol; 2001 Oct 01; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [Abstract] [Full Text] [Related]

  • 19. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
    Guilhot F.
    Bull Cancer; 2001 Jul 01; 88(7):659-60. PubMed ID: 11495817
    [No Abstract] [Full Text] [Related]

  • 20. [The Philadelphia chromosome: from the gene to therapeutic methods].
    Pérez-Losada J, González-Sarmiento R, Sánchez-García I.
    Sangre (Barc); 1998 Apr 01; 43(2):127-35. PubMed ID: 9656774
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.